Head and Neck Carcinomas

Head and neck carcinomas are a broad category of malignancies of the upper aerodigestive tract. They include squamous cell carcinoma arising from the mucosal surfaces of the oral cavity, pharynx, larynx, nasal cavity and paranasal sinuses, together with malignancies of the salivary glands and thyroid.

This entry provides the shared epidemiological, staging and multidisciplinary management framework that underpins the more detailed, site-specific considerations. Risk factor profile, diagnostic approach and treatment philosophy are largely shared across this anatomically diverse group. All are managed through structured, coordinated multidisciplinary team input.

Epidemiology and shared risk factors

• Tobacco use and alcohol consumption are the dominant traditional risk factors across most head and neck squamous cell carcinoma subsites. Their combination has a well established synergistic carcinogenic effect on the mucosa. The attributable risk varies somewhat between subsites.
• Human papillomavirus, predominantly type 16, is an increasingly important distinct aetiological factor, particularly for oropharyngeal carcinoma. Human papillomavirus associated disease carries a more favourable prognosis and needs specific consideration in treatment planning.
• Betel nut (areca nut) chewing is an important, regionally significant risk factor for oral cavity carcinoma, particularly in South and Southeast Asian populations.
• Epstein-Barr virus infection is the dominant aetiological association for nasopharyngeal carcinoma, addressed under pharyngeal cancer. Risk factors therefore vary geographically and culturally.
• Field cancerisation is the concept that the entire upper aerodigestive tract mucosa is exposed to the same carcinogenic insult in patients with significant tobacco and alcohol exposure. It underlies the elevated risk of synchronous and metachronous second primary malignancy in this tract.
• Field cancerisation directly informs the standard practice of full panendoscopy at initial diagnosis, addressed under pharyngeal cancer. It also drives the need for ongoing, structured surveillance after successful treatment of an index tumour.

• Presenting symptoms vary substantially with the anatomical subsite involved.
• Shared warning features warranting prompt assessment are a persistent (beyond three weeks) unexplained neck mass, persistent hoarseness, persistent mouth ulcer or oral lesion, unexplained dysphagia or odynophagia, unexplained otalgia, and unexplained weight loss.
• A persistent neck mass in an adult, particularly with relevant risk factors, is head and neck malignancy until proven otherwise. It may be primary nodal disease such as lymphoma or, more commonly, metastatic spread from a primary mucosal head and neck squamous cell carcinoma.
• A persistent neck mass warrants prompt, structured investigation rather than a period of watchful waiting, particularly in the relevant age and risk factor demographic.
• Significant weight loss and general functional decline frequently accompany more advanced disease. They reflect direct mechanical impact of the tumour on swallowing and nutrition, and the systemic effect of advanced malignancy.
• Proactive nutritional assessment and support are an integral part of management from the point of diagnosis.

• Initial diagnostic approach is a full head and neck examination, including flexible nasendoscopy, together with fine needle aspiration cytology of any palpable neck mass.
• Once assessment identifies a suspicious lesion, formal panendoscopy under general anaesthesia is the standard diagnostic and staging procedure. It includes biopsy of the primary lesion and examination of the entire upper aerodigestive tract to exclude a synchronous second primary tumour.
• Cross-sectional imaging (magnetic resonance imaging or computed tomography, according to subsite and clinical question) supports tumour, nodal and distant metastatic staging and informs treatment planning.
• For staging of more advanced or high-risk disease, positron emission tomography combined with computed tomography is added.
• Human papillomavirus testing is done on tumour tissue and, where relevant to the subsite, Epstein-Barr virus testing.
• Histopathological assessment includes tumour grade and the presence or absence of adverse features: perineural or lymphovascular invasion, and extracapsular nodal extension. Both carry important prognostic and treatment implications.

• Management is delivered through structured multidisciplinary team discussion. The team includes head and neck surgery, radiation oncology and medical oncology, with integrated allied health input from speech and language therapy, dietetics and, where relevant, clinical psychology and specialist head and neck nursing.
• Both the malignancy and its treatment have a substantial, often complex impact on speech, swallowing, appearance and quality of life.
• Treatment modalities are surgery, radiotherapy and systemic therapy (chemotherapy and, increasingly, targeted and immunotherapy agents), in various combinations according to tumour stage, location and biology. Selection follows the standard principles for the underlying condition.
• Early stage disease is frequently managed with single modality treatment (surgery or radiotherapy alone). More advanced disease generally requires combined modality treatment.
• Supportive and rehabilitative care is an integral and often underemphasised component throughout and beyond acute treatment. It covers swallowing dysfunction, speech and voice rehabilitation, and nutritional support, with proactive consideration of feeding tube support where significant treatment related dysphagia is anticipated.
• Dental assessment and optimisation before radiotherapy is needed given osteoradionecrosis risk. Psychological support is needed given the impact on appearance, communication and daily function.
• Structured, long term surveillance after treatment includes regular clinical and endoscopic examination, with imaging where clinically indicated. It supports early identification of disease recurrence and of any second primary malignancy in the field cancerised upper aerodigestive tract.
• Smoking and alcohol cessation support is an essential, ongoing component of long term management, given its direct relevance to recurrence risk and second primary malignancy risk.